CN114128882A - Cistanche probiotic chewable tablet with laxative properties and preparation method and application thereof - Google Patents
Cistanche probiotic chewable tablet with laxative properties and preparation method and application thereof Download PDFInfo
- Publication number
- CN114128882A CN114128882A CN202010925660.6A CN202010925660A CN114128882A CN 114128882 A CN114128882 A CN 114128882A CN 202010925660 A CN202010925660 A CN 202010925660A CN 114128882 A CN114128882 A CN 114128882A
- Authority
- CN
- China
- Prior art keywords
- cistanche
- parts
- chewable tablet
- probiotic
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000005787 Cistanche Species 0.000 title claims abstract description 81
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 70
- 239000006041 probiotic Substances 0.000 title claims abstract description 66
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 66
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 58
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims description 18
- 230000002475 laxative effect Effects 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 43
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 42
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 38
- 206010010774 Constipation Diseases 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 22
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 21
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 19
- 239000004471 Glycine Substances 0.000 claims abstract description 19
- 239000000600 sorbitol Substances 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 235000013336 milk Nutrition 0.000 claims abstract description 14
- 239000008267 milk Substances 0.000 claims abstract description 14
- 210000004080 milk Anatomy 0.000 claims abstract description 14
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 10
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 10
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000008939 whole milk Nutrition 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 230000013872 defecation Effects 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 241000336291 Cistanche deserticola Species 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims 3
- 229940125722 laxative agent Drugs 0.000 claims 3
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 230000002040 relaxant effect Effects 0.000 abstract description 16
- 241000336315 Cistanche salsa Species 0.000 abstract description 14
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 230000035764 nutrition Effects 0.000 abstract description 3
- 235000011194 food seasoning agent Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000003814 drug Substances 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 210000000813 small intestine Anatomy 0.000 description 12
- 230000000968 intestinal effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 6
- -1 liquid paraffin Chemical compound 0.000 description 6
- 229960004192 diphenoxylate Drugs 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000008855 peristalsis Effects 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010016100 Faeces discoloured Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000006693 Cassia laevigata Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 244000168525 Croton tiglium Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000735631 Senna pendula Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 235000021485 packed food Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001141 propulsive effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008143 stimulant laxative Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses desert cistanche probiotic chewable tablets with the function of relaxing bowel, which comprise the following components in parts by weight: 0.5-10 parts of cistanche dry powder, 0.5-5 parts of rhamnose bacillus, 0.5-5 parts of lactobacillus salivarius, 1-5 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate and 95% ethanol. The cistanche salsa probiotic chewable tablet is prepared by taking cistanche salsa dry powder as a raw material, adding rhamnosus, lactobacillus salivarius, sorbitol, whole milk powder, glycine, magnesium stearate and the like, mixing and tabletting, and has good intestine moistening and bowel relaxing effects due to the mutual cooperation of the raw materials, and has good prevention and treatment effects on constipation. The invention combines the cistanche and the probiotics, strengthens the effect of the cistanche on relaxing bowels, adds the milk powder, the sorbitol and the glycine to replace the sugar for seasoning, and integrates the taste, the nutrition and the effect.
Description
Technical Field
The invention relates to the technical field of food processing, in particular to desert cistanche probiotic chewable tablets with the function of relaxing bowel and a preparation method and application thereof.
Background
Functional Constipation (FC) is often caused by non-organic causes, and is clinically classified into a delayed evacuation type, a functional outlet obstruction type, and a mixed type. Functional constipation is a common and frequently encountered disease in clinic. In recent years, the global incidence of constipation has increased year by year due to changes in dietary structure, increased mental and social pressures, decreased physical activity of people and accelerated aging of society. Constipation can occur in people of any age, but the proportion of constipation in the elderly is higher, which is 2-3 times that in young and strong years. The functional constipation is caused by the slow running of food residues in the intestines due to the factors such as the intestinal hypofunction of the old, the lack of dietary fibers and the insufficient water absorption, the lack of water in the body and the insufficient defecation power. In recent years, researches show that the current western medicines have the characteristics of rapidness and good curative effect on constipation, but are unsatisfactory for the slow peristalsis of the intestinal tract and the regulation of the integral functions of the intestinal tract mainly comprising the functional disorder of the intestinal tract, obvious adverse reactions can be generated after long-term application, and the medicines circularly stimulate the intestinal tract for a long time, so that the functional disorder of the intestinal tract is easily induced, and the constipation is further aggravated. Clinically, about 20 to 40 percent of functional constipation can cause colon cancer, which endangers the life of patients. The stimulant laxative comprises anthraquinone and oleum ricini, and can directly stimulate colonic mucosa to promote peristalsis and reduce water absorption in intestinal cavity. For patients with functional constipation, the traditional Chinese medicine can quickly relieve symptoms, but adverse reactions such as abdominal pain and electrolyte disorder are easy to occur, and the traditional Chinese medicine also has a carcinogenic risk after being used for a long time.
Therefore, the development of a functional food which has the effects of intervening and relieving constipation and regulating the whole function of the intestinal tract, has low toxic and side effects and higher nutritional value is a problem which needs to be solved urgently at present.
At present, the main components of the drugs commonly used for preventing and treating constipation in the market comprise magnesium sulfate, liquid paraffin, glycerol, rhubarb, senna leaf, croton and the like, although the drugs can achieve the effect of quickly relaxing the bowels, the drugs have strong stimulation effect on the inner wall of the intestinal tract, and the drugs taken for a long time destroy the automatic defecation function of the human body, are easy to generate drug dependence, can also damage the peripheral nerve of the intestinal tract, interfere the normal function of the intestinal tract and influence the health of the human body.
In recent years, research has found that in the aspect of relieving functional constipation, besides the change of dietary habits, the proposal is made that enough dietary fiber and water are taken in daily diet, and functional food for relaxing bowel, such as food or supplement rich in probiotics, prebiotics, vitamins and phytochemicals, is appropriately supplemented.
Probiotics are a class of active microorganisms beneficial to the host, have various biological activities, and are widely applied to food, medicines, health products and animal feeds. The probiotics can be effectively planted in the intestinal tract of a human body, can inhibit the propagation of harmful bacteria in the intestinal tract, improve the intestinal flora, reduce toxins, protect the intestinal mucosa and promote the intestinal peristalsis, so that the intestinal function is improved, the defecation condition is improved, and the probiotics can be applied to preventing and treating functional constipation.
The herba cistanches is succulent stem with scale leaf of Cistanchis herba of Orobanchaceae Y.C.Ma or Cistanchis herba of Schenk R.Wight. It is warm in nature, bitter and salty in taste, and enters kidney and large intestine meridians. Has effects of invigorating kidney yang, replenishing essence and blood, loosening bowel to relieve constipation, etc. It is often used for kidney yang deficiency, essence and blood deficiency, impotence, infertility, soreness and weakness of waist and knees, weakness of tendons and bones, constipation due to intestinal dryness. Cistanche deserticola belongs to the traditional Chinese medicine for relaxing bowel, has the characteristics of mild action and no diarrhea, and is particularly suitable for treating constipation of the old, the lying-in woman, the weak people and the like.
Disclosure of Invention
In order to solve the technical problems, the cistanche salsa probiotic chewable tablet with the function of relaxing bowel is prepared by taking dry cistanche salsa powder as a raw material, adding rhamnosus, lactobacillus salivarius, sorbitol, whole milk powder, glycine, magnesium stearate and the like, mixing and tabletting, and belongs to functional food. The raw materials are matched with each other, so that the health-care tea has a good effect of relaxing bowel, and has a good prevention and treatment effect on constipation.
In order to achieve the purpose, the invention provides a desert cistanche probiotic chewable tablet with the function of relaxing bowel, which comprises the following components in parts by weight: 0.5-5 parts of cistanche dry powder, 0.5-5 parts of rhamnose bacillus, 0.5-5 parts of lactobacillus salivarius, 1-5 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate and 95% ethanol.
In the desert cistanche probiotic chewable tablet with the function of relaxing bowel provided by the invention, the desert cistanche probiotic chewable tablet comprises the following components in parts by weight: 0.5-1 part of cistanche dry powder, 0.5-1 part of rhamnose bacillus, 0.5-1 part of lactobacillus salivarius, 1-2 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate and 95% ethanol.
In the desert cistanche probiotic chewable tablet with the function of relaxing bowel provided by the invention, the desert cistanche probiotic chewable tablet comprises the following components in parts by weight: 4-5 parts of cistanche dry powder, 2-3 parts of rhamnose bacillus, 2-3 parts of lactobacillus salivarius, 2-3 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate and 95% ethanol.
In the desert cistanche probiotic chewable tablet with the function of relaxing bowel provided by the invention, the desert cistanche probiotic chewable tablet comprises the following components in parts by weight: 10 parts of cistanche dry powder, 4-5 parts of rhamnose bacillus, 4-5 parts of lactobacillus salivarius, 4-5 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate and 95% ethanol.
The invention also provides a preparation method for preparing the desert cistanche probiotic chewable tablet, which comprises the following steps:
preparing cistanche salsa freeze-dried powder by taking fresh cistanche salsa as a raw material;
weighing rhamnose bacillus, lactobacillus salivarius, sorbitol, whole milk powder, glycine and magnesium stearate in proportion, mixing, adding the cistanche freeze-dried powder, slowly pouring 95% ethanol, and making into wet mixed material;
sieving the mixed wet mixed material for granulation;
putting the prepared particles into a constant-temperature drying oven at 45 ℃ for drying and granulating;
adding magnesium stearate, fully shaking up, and then putting into a single-punch tablet machine for tabletting to obtain the desert cistanche probiotic chewable tablets.
In the preparation method provided by the invention, the steps of preparing the cistanche salsa freeze-dried powder by taking fresh cistanche salsa as a raw material comprise:
taking fresh cistanche as a raw material of dry cistanche powder, slicing, placing in a refrigerator at the temperature of minus 80 ℃ to pre-cool the cistanche for 24h, placing in a vacuum freeze dryer, drying for 72h, taking out, crushing by a crusher, and sieving by a 100-mesh sieve to obtain the dry cistanche powder.
The invention also provides application of the desert cistanche probiotic chewable tablet in preventing and treating functional constipation.
The desert cistanche probiotic chewable tablet with the function of relaxing bowel, the preparation method and the application thereof have the following beneficial effects:
(1) the cistanche deserticola in the genuine producing area is selected, freeze-dried powder is adopted as raw material components to be mild, and auxiliary materials such as rhamnose bacillus, lactobacillus salivarius, sorbitol, milk powder, glycine, magnesium stearate and the like are added, and the cistanche deserticola is prepared by a series of processes such as mixing, granulating, drying, granulating, tabletting and the like and can be directly eaten;
(2) the method of low-temperature drying is adopted in the granulating process, so that the nutritional ingredients of the raw materials cannot be damaged;
(3) the chewable tablet is prepared by selecting purely natural food materials and using a scientific formula, contains rich nutrient components, is mutually matched with probiotics, and is convenient to carry by intervening a constipation mouse model induced by compound diphenoxylate, and the result shows that the cistanche probiotic chewable tablet provided by the invention increases the intestinal propulsion of a constipation mouse, shortens the first black excrement discharge time, increases the number of excrement granules within 6h, softens the excrement of the constipation mouse, and shows the typical effect of relaxing bowel.
Detailed Description
The present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
It should be understood that the embodiments and specific features in the embodiments of the present invention are described in detail in the present application, but not limited to the present application, and the features in the embodiments and specific features in the embodiments of the present invention may be combined with each other without conflict.
Example 1 preparation of desert cistanche probiotic chewable tablets 1
1. Material
The strain required in the examples is rhamnosus (Lactobacillus rhamnosus) with the accession number CTCC 6133; lactobacillus salivarius (Lactobacillus salivarius) with the preservation number JCM1213, provided by microbial strain preservation center of Guangdong province, and Cistanchis herba is collected from inner Mongolia and identified as Cisanche deseristiola Y.C.Ma succulent stem by Fei professor Tupeng of Beijing university.
2. Experimental methods
2.1. Determination of raw material ratio
The desert cistanche probiotic chewable tablet 1 comprises, by weight, 0.5-1 part of desert cistanche dry powder, 0.5-1 part of rhamnose bacillus, 0.5-1 part of lactobacillus salivarius, 1-2 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate and a proper amount of 95% ethanol.
2.2. Preparation process of desert cistanche probiotic chewable tablets
Taking fresh cistanche as a raw material of dry cistanche powder, slicing, placing in a refrigerator at-80 ℃ to pre-cool the cistanche for 24h, placing in a vacuum freeze dryer (the vacuum degree is 600Pa, the freezing temperature is-56 ℃), drying for 72h, taking out, crushing by a crusher, and sieving by a 100-mesh sieve to obtain the dry cistanche powder; weighing rhamnose bacillus, lactobacillus salivarius, sorbitol, whole milk powder, glycine and magnesium stearate according to a certain proportion, mixing for 20min, slowly pouring 95% ethanol to prepare a wet mixed material, and granulating the mixed material through a 20-mesh sieve; drying the prepared granules in a constant-temperature drying box at 45 ℃ and finishing the granules; sieving with 20 mesh sieve and 80 mesh sieve; and adding 0.05 part of magnesium stearate into the mixed material, fully shaking up, putting into a single-punch tablet machine for tabletting, and thus obtaining the desert cistanche probiotic chewable tablet. The chewable tablets were bottled after 20min uv irradiation, the experimental procedure in this example was carried out at a department of chezhou and leonku food ltd, complying with the SC standard.
Example 2 preparation of desert cistanche probiotic chewable tablets 2
1. Material
The required materials were the same as described in example 1.
2. Experimental methods
2.1. Determination of raw material ratio
The difference between the embodiment and the embodiment is that the cistanche salsa probiotic chewable tablet 2 comprises, by weight, 4-5 parts of cistanche salsa dry powder, 2-3 parts of rhamnosus, 2-3 parts of lactobacillus salivarius, 2-3 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate, and a proper amount of 95% ethanol.
2.2. Preparation process of desert cistanche probiotic chewable tablets
The preparation method of the desert cistanche probiotic chewable tablet 2 is as described in the preparation method of the example 1.
Example 3 preparation of desert cistanche probiotic chewable tablets 3
1. Material
The required materials were the same as described in example 1.
2. Experimental methods
2.1. Determination of raw material ratio
The difference between the embodiment and the embodiment is that the cistanche salsa probiotic chewable tablet 3 comprises, by weight, 10 parts of cistanche salsa dry powder, 4-5 parts of rhamnosus, 4-5 parts of lactobacillus salivarius, 4-5 parts of sorbitol, 0.5-1 part of milk powder, 0.02-0.05 part of glycine, 0.05-0.1 part of magnesium stearate, and a proper amount of 95% ethanol.
2.2. Preparation process of desert cistanche probiotic chewable tablets
The preparation method of the desert cistanche probiotic chewable tablet 3 is as described in the preparation method of the example 1.
Example 4 determination of nutritional ingredients of desert cistanche probiotic chewable tablets
1. Material
Cistanche probiotic chewable tablets 1, one production of example, batch number S2020011701, cistanche probiotic chewable tablets 2, one production of example two, batch number S2020011702, cistanche probiotic chewable tablets 3, one production of example three, and batch number S2020011703.
2. Experimental methods
According to the GB 28050 plus 2011 national standard for food safety standard, the general rule of pre-packaged food nutrition labels, Shanghai Biao product detection Limited company is entrusted to carry out nutrition component detection on the desert cistanche probiotic chewable tablets of the three embodiments. The protein content is measured by a first GB/T5009.5-2016 method; a first method for measuring the fat content GB/T5009.6-2016; the definition of energy is calculated by GB/Z21922-2008; the method for measuring the sodium content adopts a GB/T5009.91-2007 first method; the moisture content is measured by a first method of GB/T5009.3-2016; the ash content is measured by the first method of GB/T5009.3-2016.
3. Results of the experiment
3.1. Analysis of nutrient components of desert cistanche probiotic chewable tablets
The nutrient component analysis of the desert cistanche probiotic chewable tablet is shown in table 1.
TABLE 1 desert cistanche chewing tablets nutrient composition
Example 5 intervention of Cistanchis herba probiotic chewable tablet on Constipation mice
1. Material
1.1. Medicine and food additive
The batch numbers of the cistanche salsa probiotic chewable tablets in the embodiment 3 are respectively the same as those in the embodiments 1, 2 and 3; compound diphenoxylate, available from yokoku pharmaceutical co ltd, lot number national drug standard H22037; molsidine, available from west ann poplar pharmaceutical co ltd, lot No. 20013876; blue ink (marker) diluted 65% in concentration.
1.2. Raising of animals
The method is characterized in that male mice of Kunming species are selected, 8 weeks old, 25 +/-5 g in weight, purchased from Kangmeihua Dagenetechnology Limited company, and provided with license number SYXK (Guangdong) 2020-.
2. Experimental methods
2.1 Small intestine Propulsion experiment
Experimental mice were randomly divided into 6 groups of 10 mice each. The experiment is provided with a normal control group, a constipation model group, 3 desert cistanche probiotic chewable tablet groups and a positive medicine group. Wherein the normal group is distilled water, the dosage of the 3 cistanche probiotic chewable tablet groups is 1g/kg BW, the distilled water is used for preparing 0.2mL of intragastric solution, and the positive group is 0.5 mg/L of morpholine aqueous solution. After each group was gavaged for 14 days, mice in each group were fasted for 16h, except for the normal group, gavaged with 10mg/kg of compound diphenoxylate and the control group with distilled water of the corresponding volume. After 30min of the gavage compound diphenoxylate, 0.2mL of blue ink is given to each dosage group, after 25 min of gavage with ink, the mouse is killed by cervical dislocation, the mesentery and part of small intestine (pylorus to ileocecum) are taken, the obtained small intestine is placed on a tray and is slightly pulled to be in a straight line, the length of the small intestine is measured and is the total length of the small intestine, the length from the pylorus to the front edge of the activated carbon is the ink propulsion length, and the ink propulsion rate is calculated according to the following formula:
the ink propulsion rate (%) is ink propulsion length (cm)/total small intestine length (cm) × 100%
2.2 measurement of defecation time and number of grains of feces
The mouse molding method was the same as that in section "2.1" of example 5, and the defecation time, total number of first black stools and properties (soft stools or loose stools) within 6 hours after gastric lavage of ink were recorded for each mouse. Compared with a model group, the water content of the excrement is less than 55 percent, the excrement is soft, and the water content of the excrement is greater than or equal to 55 percent, and the excrement is loose.
2.3 determination of intestinal Water content in mice
The mouse model was made as described in example 5, section "2.1". Respectively and randomly killing half of animals of each group 3h and 5h after the compound diphenoxylate gavage by adopting a cervical dislocation method, cutting off an intestinal canal from a pylorus, separating to the tail end of a rectum, separating large and small intestines, respectively weighing the wet weights, drying at 105 ℃ to constant weight, weighing the dry weights of the large and small intestines, and calculating the water content according to the following formula:
intestine water content (%) - (intestine wet weight (g) -intestine dry weight (g))/intestine wet weight (g) × 100%
2.4. Observation of mouse body weight and general conditions
The weights of the mice in each experimental group before and after the experiment were recorded, and the feeding condition, the response sensitivity and the fur gloss condition of the mice were observed.
2.5. Statistical analysis of data
The data analysis is carried out by adopting SPSS 20.0 statistical software, and the data are all expressed as mean value plus or minus standard deviation
Expressing that a single sample K-S test is adopted for carrying out normality test, normal distribution data is subjected to one-factor variance analysis, data which does not meet normal distribution is subjected to nonparametric test, P<The difference is obvious at 0.05, and the statistical significance is achieved.
3. Results of the experiment
3.1. Influence of desert cistanche chewing tablet on small intestine propulsion of mouse
The results of the effect of the desert cistanche probiotic chewable tablets on the intestinal propulsion of the constipation mice are shown in table 2. As shown in Table 2, the intestinal charcoal propulsion rate of the constipation model group mice is significantly lower than that of the control group (P <0.05), indicating that the constipation model is successfully established. Compared with the model group, the chewable tablet groups and the positive medicine groups thereof can enhance the propulsive peristalsis of the small intestine, increase the propulsion length of the ink and improve the propulsion rate of the ink. Wherein, the chewable tablets 2 and 3 have significant difference (P <0.05) compared with the positive group and the model group, which shows that the desert cistanche probiotic chewable tablets have the function of promoting the intestinal movement of constipation mice.
Table 2 effect of desert cistanche probiotic chewable tablets on small intestine propulsion of constipation mice (n ═ 10)
Note: compared with the normal control group, the composition has the advantages that,#represents P<0.05; in comparison to the set of models,*represents P<0.05
3.2. Influence of desert cistanche chewing tablets on defecation of mice
After the mice were perfused with the ink for 6h, each mouse was observed for the discharge of black feces, and the discharge time of the first black feces was recorded. The effect of the desert cistanche probiotic chewable tablets on the defecation of the constipation mice is shown in table 3. The results of the discharge time of the first black feces of the mouse and the number of the first black feces of the mouse in 6h show that compared with the control group, the time of the first black feces of the mouse in the model group is obviously delayed, the number of the first black feces of the mouse in 6h is obviously reduced, and the two indexes have significant difference (P is less than 0.05) between the control group and the model group, which shows that the constipation model of the mouse is successfully established. Compared with the model group, the first black excrement discharge time of each group of chewable tablets and the positive medicine group thereof is shortened, and the number of the excrement discharge granules in 6 hours is increased. Wherein, chewable tablet 3, the first black stool discharging time and the number of 6h stool discharging grains of the positive group mouse have significant difference compared with the model group (P < 0.05). In 6h defecation time of the mice, compared with the model group, the water content of the excrement of each group of the chewable tablets and the positive medicine group of the mice is gradually increased, and the excrement is soft. The results show that the cistanche salsa probiotic chewable tablets can obviously shorten the first black excrement discharge time of a constipation mouse, increase the number of excrement discharge granules within 6 hours, soften the excrement of the constipation mouse and show the typical defecation effect.
Table 3 effect of desert cistanche probiotic chewable tablets on defecation of constipated mice (n ═ 10)
Note: compared with the normal control group, the composition has the advantages that,#represents P<0.05; in comparison to the set of models,*represents P<0.05
3.3. Influence of desert cistanche probiotic chewable tablets on water content of intestinal tract of mouse
Half of the animals in each group were sacrificed randomly 3 hours and 5 hours after the intragastric administration of each group, respectively, by cervical dislocation, and the water content of the intestinal tract was measured, and the results are shown in table 4. As can be seen from the data in the table, the effect of the chewable tablet groups and the positive groups thereof on the water content of the large intestine and the small intestine of the mice is not significant, which is consistent with the result of the water content of the feces in the table 3, and this may be related to the free water drinking of the mice during the experiment.
Table 4 effect of desert cistanche probiotic chewable tablets on water content of constipation mouse intestinal tract (n ═ 10)
3.4 mouse body weight and general Condition observations
In this study, the weight gain of the chewable tablet in each group and the positive group of mice was not significantly different from that in the control group and the model group (table 5). During the experiment, no mouse death phenomenon exists, the health condition is good, the appetite is strong, the response is sensitive, and the fur is glossy.
Table 5 effect of desert cistanche probiotic chewable tablets on body weight of constipated mice (n ═ 10)
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010925660.6A CN114128882A (en) | 2020-09-03 | 2020-09-03 | Cistanche probiotic chewable tablet with laxative properties and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010925660.6A CN114128882A (en) | 2020-09-03 | 2020-09-03 | Cistanche probiotic chewable tablet with laxative properties and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114128882A true CN114128882A (en) | 2022-03-04 |
Family
ID=80438496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010925660.6A Pending CN114128882A (en) | 2020-09-03 | 2020-09-03 | Cistanche probiotic chewable tablet with laxative properties and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114128882A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116870053A (en) * | 2023-06-20 | 2023-10-13 | 山东第一医科大学附属省立医院(山东省立医院) | Medicine for improving sexual function and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853492A (en) * | 2005-04-29 | 2006-11-01 | 浙江山下湖珍珠集团股份有限公司 | Pearl-milk chewing tablets |
| WO2008052468A1 (en) * | 2006-11-01 | 2008-05-08 | Sine Pharmaceutical Laboratories | New lactobacillus rhamnosus strain, its pharmaceutical composition and the uses thereof, and the method for preparation |
| CN104366486A (en) * | 2014-12-10 | 2015-02-25 | 孙伟 | Formula and preparation method of quintuplet probiotic chewable tablet |
| CN108477617A (en) * | 2018-03-16 | 2018-09-04 | 武汉虹辰远荣生物制品有限公司 | A kind of probiotic powder and preparation method thereof to relax bowel |
| CN108671029A (en) * | 2018-07-01 | 2018-10-19 | 甘肃农业大学 | Herba Cistanches chewable tablets and preparation method thereof |
| CN108741047A (en) * | 2018-07-01 | 2018-11-06 | 甘肃农业大学 | A kind of quinoa desert cistanche chewable tablets and preparation method thereof |
| CN110959866A (en) * | 2019-11-22 | 2020-04-07 | 北京海德恒生科技发展有限公司 | High-fiber chewable tablet containing probiotics and preparation method thereof |
| CN111296847A (en) * | 2020-03-23 | 2020-06-19 | 吉林省浦生泰生物技术有限责任公司 | Cereal probiotic preparation for regulating intestinal microecology and preparation method and application thereof |
-
2020
- 2020-09-03 CN CN202010925660.6A patent/CN114128882A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853492A (en) * | 2005-04-29 | 2006-11-01 | 浙江山下湖珍珠集团股份有限公司 | Pearl-milk chewing tablets |
| WO2008052468A1 (en) * | 2006-11-01 | 2008-05-08 | Sine Pharmaceutical Laboratories | New lactobacillus rhamnosus strain, its pharmaceutical composition and the uses thereof, and the method for preparation |
| CN104366486A (en) * | 2014-12-10 | 2015-02-25 | 孙伟 | Formula and preparation method of quintuplet probiotic chewable tablet |
| CN108477617A (en) * | 2018-03-16 | 2018-09-04 | 武汉虹辰远荣生物制品有限公司 | A kind of probiotic powder and preparation method thereof to relax bowel |
| CN108671029A (en) * | 2018-07-01 | 2018-10-19 | 甘肃农业大学 | Herba Cistanches chewable tablets and preparation method thereof |
| CN108741047A (en) * | 2018-07-01 | 2018-11-06 | 甘肃农业大学 | A kind of quinoa desert cistanche chewable tablets and preparation method thereof |
| CN110959866A (en) * | 2019-11-22 | 2020-04-07 | 北京海德恒生科技发展有限公司 | High-fiber chewable tablet containing probiotics and preparation method thereof |
| CN111296847A (en) * | 2020-03-23 | 2020-06-19 | 吉林省浦生泰生物技术有限责任公司 | Cereal probiotic preparation for regulating intestinal microecology and preparation method and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116870053A (en) * | 2023-06-20 | 2023-10-13 | 山东第一医科大学附属省立医院(山东省立医院) | Medicine for improving sexual function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102823779B (en) | Dairy cow feed, preparation method and traditional Chinese medicine for improving dairy cow production performance | |
| CN103355552B (en) | Mixed feed for carp in fingerling stage and preparation method thereof | |
| CN103355556A (en) | Corn type mixed feed for weaned pig and preparation method thereof | |
| CN104524110A (en) | Traditional Chinese medicine composition with functions of tonifying spleen and clearing damp | |
| CN104431586A (en) | Piglet compound feed and preparation method thereof | |
| WO2014190935A1 (en) | Multi-functional composition and preparation method and application thereof | |
| KR20160037510A (en) | Fermented foods improve bowel function and a method of manufactuing stercoral removal efficacy | |
| US10406195B2 (en) | Solid drink for regulating phlegm-dampness constitution and processing method thereof | |
| CN105079309B (en) | Composition for relaxing bowel | |
| CN101642252B (en) | Health-care food of bitter buckwheat granules | |
| CN104256165A (en) | Functional feed for preventing and treating chronic swine plague and preparation method of functional feed | |
| CN108245531B (en) | Composition for improving gastrointestinal tract function and preventing and treating constipation | |
| CN110338284A (en) | A kind of mongolian veterinary drug feed addictive and preparation method and application for preventing and treating sheep urinary calculus | |
| CN105028995A (en) | Mixed dog food and preparation method thereof | |
| CN114128882A (en) | Cistanche probiotic chewable tablet with laxative properties and preparation method and application thereof | |
| KR101487769B1 (en) | Food Composition for Bowel Movement Promotion and Diet using Aspergillus oryzae | |
| CN103977372A (en) | Traditional Chinese medicine additive used for treating porcine epizootic diarrhea and preparing method thereof | |
| CN117481342A (en) | Composition for reducing side effects of drug vomiting as well as preparation method and application thereof | |
| CN104970220A (en) | Compound feed for sows in suckling period and preparation method thereof | |
| KR20100094223A (en) | The drinking water composition for dissolution of hangover | |
| CN104173905B (en) | A kind of Chinese and Western medicine composite preparation for treating constipation and preparation method thereof | |
| CN102488767B (en) | Compound composition for treating bacterial diarrhoea of livestock and poultry | |
| CN104940332B (en) | A kind of fructooligosaccharide composition for laxative and reducing flatulence and preparation method thereof | |
| CN109620858A (en) | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes | |
| CN113827635B (en) | Traditional Chinese medicine composition for relaxing bowels and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |